Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Alfred L. Garfall(University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania)
Cited by 74
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
|Nature Medicine|2021|519
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
|Nature Medicine|2024|254